Climb Bio CLYM 深 沪
已收盘 07-02 16:00:00 美东时间
12.90
-0.390
-2.93%
华盛通- 最 高13.49
- 今 开13.095
- 成交量 117.67万股
- 最 低 12.43
- 昨 收 13.29
- 总市值 7.39亿
- 52周最高 13.69
- 市盈率 静 --
- 换手率 2.05%
- 52周最低 1.35
- 委 比 -82.59%
- 总股本 5726.30万
- 历史最高 29.69
- 量 比 0.48
- 振 幅 7.98%
- 历史最低 1.05
- 每 手 1
- 风险率 3.60%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 瑞银上调超微公司目标价从455美元升至670美元，上调ARM目标价从260美元升至470美元；美银证券上调台积电目标价从490美元升至590美元
今日重点评级关注：Jones Trading：维持Definium Therapeutics"买入"评级，目标价从61美元升至74美元；韦德布什：维持Cerebras Systems"跑赢大市"评级，目标价从270美元升至280美元
06-25 11:32
HC Wainwright & Co. Reiterates Buy on Climb Bio, Maintains $20 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Climb Bio (NASDAQ:CLYM) with a Buy and maintains $20 price target.
06-24 18:50
美股大行评级 | Adobe惨遭18家大行下调目标价！CFRA首予SpaceX(SPCX)"卖出"评级，目标价115美元
今日重点评级关注：Piper Sandler：维持Tenax Therapeutics"超配"评级，目标价从20美元升至50美元；Tigress Financial：维持优步"买入"评级，目标价从110美元升至115美元
06-15 08:32
Climb Bio Establishes New At-the-Market Equity Program
Climb Bio ( ($CLYM) ) has provided an announcement. On June 12, 2026, Climb Bio...
06-13 06:46
Climb Bio Launches $100M At-The-Market Common Stock Offering Via Jefferies
Up to $100,000,000 Common Stock We have entered into an Open Market Sale AgreementSM, or the Sales Agreement, with Jefferies LLC, or Jefferies, dated as of June 12, 2026, relating to the sale of shares of our common stock, par value $0.0001 per share, offered by this prospectus supplement and the ...
06-13 04:25
Why Is Climb Bio Stock Gaining Friday?
Climb Bio Inc. (NASDAQ:CLYM) on Thursday shared initial data from its ongoing Phase 1b portion of its Phase 1b/2a study of budoprutug for primary immune thrombocytopenia (ITP), an autoimmune disorder where the immune system mistakenly attacks and destroys platelets. The data show a favorable safety ...
06-12 22:19
Wedbush Reiterates Outperform on Climb Bio, Maintains $17 Price Target
Wedbush analyst Laura Chico reiterates Climb Bio (NASDAQ:CLYM) with a Outperform and maintains $17 price target.
06-12 21:59
美股大行评级 | 甲骨文绩后分歧大！5家上调，2家下调；Navan、Hinge Health、凯西通用获多家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持Outlook Therapeutics"买入"评级，目标价从6美元升至10美元；Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从14美元升至14.5美元
06-12 11:32
美股大行评级 | 存储再获看多！美光、闪迪、西部数据获机构上调目标价；次新股Cerebras、Blackstone、EagleRock获多家机构首予买入平均
今日重点评级关注：Ascendiant Capital：维持IGC Pharma"买入"评级，目标价从5.25美元升至5.5美元；Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从9美元升至9.25美元
06-09 11:33
Climb Bio Plans To Share Initial PK/PD Data And Updated Safety Data From Ongoing Phase 1 Studies Of CLYM116 In Healthy Volunteers, At Next Installment Of Its R&D Spotlight Series
The Company also announced that it plans to share initial pharmacokinetic and pharmacodynamic (PK/PD) data, as well as updated safety data from the ongoing Phase 1 studies of CLYM116 in healthy volunteers, at the next
06-05 19:08
